MCID: LYM143
MIFTS: 72

Lymphoma, Non-Hodgkin, Familial

Categories: Genetic diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 57 38 40
Non-Hodgkin Lymphoma 57 38 12 76 15
Lymphoma, Non-Hodgkin 57 13 73
Nhl 57 75
Lymphoma, Non-Hodgkin, Somatic 57
Lymphoma, Follicular, Somatic 57
Familial Non-Hodgkin Lymphoma 75
Non-Hodgkin Lymphoma; Nhl 57
Lymphoma Non-Hodgkins 55

Classifications:



External Ids:

OMIM 57 605027
Disease Ontology 12 DOID:0060060
MedGen 42 C0024305
ICD10 33 C85.7

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot : 75 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma, hodgkin, classic and lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Mozobil and Rituxan have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are lymphoma and Decreased viability in esophageal squamous lineage

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 76 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 33.0 ALK BCL6 PAX5 PTPRC
2 lymphoma 32.9 ALK BCL10 BCL6 CASP10 CCND1 MALT1
3 mantle cell lymphoma 32.2 BCL6 CCND1 CD5 MALT1 MYC PAX5
4 non-hodgkin lymphoma, during pregnancy 12.3
5 non-hodgkin lymphoma, childhood 12.2
6 cll/sll 11.5 CCND1 CD5 PAX5 TP53
7 bladder urothelial carcinoma 11.5 BRAF CCND1 NRAS PIK3CA TP53
8 nodular lymphocyte predominant hodgkin lymphoma 11.5 BCL6 CCND1 PAX5 PTPRC
9 epidural neoplasm 11.5 BCL6 CD5 PTPRC TP53
10 ovarian serous cystadenocarcinoma 11.5 BRAF NRAS PIK3CA TP53
11 b cell prolymphocytic leukemia 11.5 CD5 MS4A1 MYC TP53
12 respiratory system cancer 11.5 ALK CCND1 MYC PIK3CA TP53
13 peripheral nervous system neoplasm 11.5 ALK MYC NRAS TP53
14 cell type cancer 11.5 ALK CCND1 MYC NRAS TP53
15 autonomic nervous system neoplasm 11.5 ALK MYC NRAS TP53
16 colon lymphoma 11.5 ALK BCL6 CD5 PTPRC
17 renal cell carcinoma, papillary, 1 11.5 BRAF NRAS PIK3CA TP53
18 mature b-cell neoplasm 11.5 BCL6 MYC PTPRC TP53
19 breast lymphoma 11.5 ALK BCL6 CD5
20 non-proliferative fibrocystic change of the breast 11.5 CCND1 NPM1 TP53
21 myeloma, multiple 11.5 BRAF CCND1 MYC NRAS PTPRC TP53
22 peripheral t-cell lymphoma 11.5 ALK BCL6 CD5 MS4A1 TP53
23 lymphoma, mucosa-associated lymphoid type 11.5 BCL10 BCL6 CCND1 CD5 MALT1
24 female reproductive organ cancer 11.5 CCND1 MYC PIK3CA TP53
25 differentiated thyroid carcinoma 11.5 ALK BRAF NRAS TP53
26 lung cancer susceptibility 3 11.5 ALK BRAF CCND1 NRAS PIK3CA TP53
27 bile duct carcinoma 11.5 CCND1 MYC PIK3CA TP53
28 inflammatory myofibroblastic tumor 11.5 ALK CCND1 NPM1 TP53
29 marginal zone b-cell lymphoma 11.5 BCL10 BCL6 CD5 MALT1
30 erdheim-chester disease 11.5 BRAF NRAS PIK3CA
31 adamantinoma of long bones 11.5 BRAF CCND1 MYC PIK3CA TP53
32 plasmablastic lymphoma 11.5 BCL6 MS4A1 MYC PTPRC
33 gastric adenocarcinoma 11.5 BRAF CCND1 MYC NRAS PIK3CA TP53
34 reticulosarcoma 11.5 ALK BCL6 NPM1 PAX5 PTPRC
35 lung lymphoma 11.5 ALK BCL6 CD5 MALT1 PAX5
36 follicular lymphoma 11.5 BCL10 BCL6 CCND1 MS4A1 MYC
37 splenic marginal zone lymphoma 11.5 BCL6 CD5 MALT1 PAX5
38 glioblastoma 11.5 ALK BRAF CCND1 MYC NRAS PIK3CA
39 adrenocortical carcinoma, hereditary 11.5 BRAF NRAS PIK3CA TP53
40 hodgkin's lymphoma, lymphocytic depletion 11.5 ALK PAX5 PTPRC
41 primary cutaneous anaplastic large cell lymphoma 11.5 ALK NPM1 PTPRC
42 diffuse large b-cell lymphoma 11.4 ALK BCL10 BCL6 CD5 MALT1 MYC
43 composite lymphoma 11.4 BCL6 CD5 PAX5
44 gastric lymphoma 11.4 BCL10 BCL6 TP53
45 hemimegalencephaly 11.4 CCND1 MYC PIK3CA
46 gastrointestinal system cancer 11.4 CCND1 MYC PIK3CA TP53
47 lymphatic system cancer 11.4 ALK BCL6 CD5 MYC NPM1 PTPRC
48 brain cancer 11.4 ALK BRAF NRAS PIK3CA TP53
49 autoimmune lymphoproliferative syndrome 11.4 CASP10 NRAS PRF1 PTPRC
50 esophagus adenocarcinoma 11.4 MYC PIK3CA TP53

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Clinical features from OMIM:

605027

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

32
# Description HPO Frequency HPO Source Accession
1 lymphoma 32 HP:0002665

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.85 PIK3CA PTPRC RAD54L TP53 BCL10 BCL6
2 Reduced mammosphere formation GR00396-S 9.5 BCL6 BRAF CCND1 CD5 MYC NRAS
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 BCL10 MALT1 RAD54B RAD54L TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 BCL10 BRAF CCND1 MALT1 MYC RAD54B

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 BCL10 BCL6 BRAF CCND1 CD5 MALT1
2 cellular MP:0005384 10.39 BCL10 BCL6 BRAF CCND1 MYC NPM1
3 immune system MP:0005387 10.38 PAX5 PIK3CA PRF1 PTPRC RAD54L TP53
4 mortality/aging MP:0010768 10.31 RAD54B RAD54L TP53 PRF1 PTPRC ALK
5 growth/size/body region MP:0005378 10.3 ALK BCL6 BRAF CCND1 MYC NPM1
6 endocrine/exocrine gland MP:0005379 10.28 PTPRC TP53 ALK BCL10 BCL6 BRAF
7 homeostasis/metabolism MP:0005376 10.27 ALK BCL6 BRAF CCND1 MYC NRAS
8 integument MP:0010771 10.16 ALK BRAF CCND1 CD5 MYC NPM1
9 neoplasm MP:0002006 10.11 ALK BRAF CCND1 MYC NPM1 NRAS
10 nervous system MP:0003631 10.1 PAX5 ALK BCL10 BRAF CCND1 CD5
11 liver/biliary system MP:0005370 10.03 BCL6 BRAF MYC NPM1 NRAS PRF1
12 normal MP:0002873 9.85 BCL6 BRAF CCND1 CD5 MYC NRAS
13 no phenotypic analysis MP:0003012 9.8 BCL6 CD5 MYC NRAS PIK3CA PTPRC
14 pigmentation MP:0001186 9.35 ALK BRAF MYC NRAS TP53
15 skeleton MP:0005390 9.28 MYC NRAS PAX5 PIK3CA PTPRC TP53

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
2
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
3
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
4
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
5
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 668)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
4
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
9
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
12
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
13
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 24356-66-9 32326 21704
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
18
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
19
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
20
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
21
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
22
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
24
Angiotensin II Approved, Investigational Phase 4,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
27
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
28
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
29
Prilocaine Approved Phase 4 721-50-6 4906
30
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
31
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
32
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
33
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
34
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
35
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
36
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
39
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
40
Pirarubicin Investigational Phase 4 72496-41-4
41 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 0
48 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2326)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
4 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
5 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
6 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
7 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
8 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
9 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
10 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
11 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
12 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
13 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
15 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
16 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
17 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4 Tenofovir
18 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
19 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Recruiting NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
20 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4 temsirolimus;temsirolimus
21 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
22 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
23 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
24 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
25 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
26 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
27 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
28 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
29 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
30 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
31 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
32 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
33 Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
34 Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
35 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
36 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
37 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
39 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
40 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
41 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
43 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
44 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
45 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
46 Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
47 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
48 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
49 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
50 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Nk Cells, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 1356)
# Title Authors Year
1
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
2
Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )
2018
3
Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review. ( 29478335 )
2018
4
Primary Cardiac B-Non-Hodgkin Lymphoma Disguised as a Pacemaker Endocarditis. ( 29977733 )
2018
5
Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )
2018
6
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
7
Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. ( 28332735 )
2018
8
Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma. ( 28679297 )
2018
9
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. ( 29978452 )
2018
10
Non-alcoholic Wernicke-Korsakoff syndrome heralding non-Hodgkin lymphoma progression. ( 29582179 )
2018
11
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? ( 29650494 )
2018
12
Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with Non-Hodgkin Lymphoma: a possible indication for prophylaxis. ( 29512976 )
2018
13
A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy. ( 29259834 )
2017
14
The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. ( 29257907 )
2017
15
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
16
Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )
2017
17
Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma. ( 28509575 )
2017
18
PI3KI'-selective and PI3KI+/I'-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. ( 28945111 )
2017
19
Pure sensory ganglionopathy as the first sign of relapse in non-Hodgkin lymphoma. ( 28507261 )
2017
20
Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma. ( 28523057 )
2017
21
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. ( 28685851 )
2017
22
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. ( 28112752 )
2017
23
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. ( 28104689 )
2017
24
Identification of a new HLA-A allele, HLA-A*02:07:09, in a Chinese non-Hodgkin lymphoma patient. ( 28677225 )
2017
25
Associations between genetic variants in immunoregulatory genes and risk of non-Hodgkin lymphoma in a Chinese population. ( 28060727 )
2017
26
Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )
2017
27
Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )
2017
28
Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. ( 28914567 )
2017
29
Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. ( 28491264 )
2017
30
Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. ( 28922087 )
2017
31
Novel Mutations in SH2D1A Gene in X-linked Lymphoproliferative Syndrome, Diagnosed After B-Cell Non-Hodgkin Lymphoma. ( 28267077 )
2017
32
Loss of Reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. ( 28498462 )
2017
33
Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. ( 28915338 )
2017
34
Breast lymphoma in a patient with B-cell Non Hodgkin Lymphoma: A case report study. ( 28915427 )
2017
35
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. ( 27558232 )
2017
36
Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. ( 27861844 )
2017
37
Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis. ( 28531181 )
2017
38
Intestinal perforation that developed after chemotherapy in a patient diagnosed with non-Hodgkin lymphoma: A case report and review of literature. ( 28898795 )
2017
39
Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. ( 28123744 )
2017
40
Non-Hodgkin lymphoma of multiple extranodal involvement seen on MRI, FDG PET-CT scans: A case report. ( 29137032 )
2017
41
TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. ( 28369138 )
2017
42
Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. ( 28535466 )
2017
43
Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. ( 28061782 )
2017
44
Dietary fat intake and risk of non-Hodgkin lymphoma in 2 large prospective cohorts. ( 28659300 )
2017
45
Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. ( 29059235 )
2017
46
Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. ( 28503716 )
2017
47
Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. ( 27943422 )
2017
48
Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. ( 28210822 )
2017
49
Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. ( 28246881 )
2017
50
Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. ( 28498337 )
2017

Variations for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

75
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6
(show top 50) (show all 106)
# Gene Variation Type Significance SNP ID Assembly Location
1 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh37 Chromosome 8, 95403868: 95403868
2 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh38 Chromosome 8, 94391640: 94391640
3 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh37 Chromosome 1, 46738430: 46738430
4 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh38 Chromosome 1, 46272758: 46272758
5 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh37 Chromosome 2, 202074111: 202074111
6 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh38 Chromosome 2, 201209388: 201209388
7 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh37 Chromosome 2, 202070652: 202070652
8 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh38 Chromosome 2, 201205929: 201205929
9 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh37 Chromosome 2, 202073912: 202073913
10 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh38 Chromosome 2, 201209189: 201209190
11 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
12 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 PRF1 NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh37 Chromosome 10, 72358355: 72358355
16 PRF1 NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh38 Chromosome 10, 70598599: 70598599
17 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
18 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
19 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
20 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
21 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
22 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
23 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
25 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
26 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
27 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
28 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
29 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 NCBI36 Chromosome 7, 148139660: 148139660
30 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
31 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
32 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 NCBI36 Chromosome 7, 148139661: 148139661
33 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
34 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
35 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
36 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
37 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh37 Chromosome 17, 7577093: 7577093
38 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh38 Chromosome 17, 7673775: 7673775
39 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
40 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
41 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh37 Chromosome 15, 66727455: 66727455
42 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh38 Chromosome 15, 66435117: 66435117
43 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
44 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
45 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
46 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
47 MYC NM_002467.5(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 GRCh38 Chromosome 8, 127738435: 127738435
48 MYC NM_002467.5(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 GRCh37 Chromosome 8, 128750681: 128750681
49 B2M NM_004048.2(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 GRCh37 Chromosome 15, 45003747: 45003747
50 B2M NM_004048.2(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 GRCh38 Chromosome 15, 44711549: 44711549

Cosmic variations for Lymphoma, Non-Hodgkin, Familial:

9
(show all 31)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 9
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 9
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 9
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 9
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 9
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 9
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 9
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 9
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 9
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 9
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 9
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 9
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 9
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 9
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 9
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 9
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 9
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 9
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 9
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 9
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 9
23 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 9
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 9
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 9
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 9
31 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 9

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 BCL10 BCL6 BRAF CASP10 CCND1 MALT1
2
Show member pathways
13.37 BCL6 BRAF CCND1 MYC NRAS PIK3CA
3
Show member pathways
12.88 BRAF CCND1 MYC NRAS PIK3CA TP53
4
Show member pathways
12.81 CASP10 MYC NRAS PIK3CA PRF1 TP53
5
Show member pathways
12.8 BCL10 BRAF MALT1 MYC NRAS PTPRC
6 12.76 ALK BRAF CCND1 MYC NRAS PIK3CA
7
Show member pathways
12.75 ALK BRAF CCND1 NRAS PIK3CA TP53
8
Show member pathways
12.74 BCL10 MALT1 NRAS PIK3CA TP53
9
Show member pathways
12.74 BRAF CCND1 MYC NRAS PIK3CA TP53
10
Show member pathways
12.72 BRAF NPM1 NRAS PIK3CA TP53
11 12.57 BCL10 BCL6 MALT1 PAX5 PTPRC
12
Show member pathways
12.53 CASP10 CCND1 MYC NRAS PIK3CA TP53
13 12.52 CCND1 MYC NRAS PIK3CA TP53
14
Show member pathways
12.44 CASP10